WO2003005032A3 - Procede de criblage de molecules aptes a se lier a la proteine gp120 du virus de l'immunodeficience - Google Patents

Procede de criblage de molecules aptes a se lier a la proteine gp120 du virus de l'immunodeficience Download PDF

Info

Publication number
WO2003005032A3
WO2003005032A3 PCT/FR2002/002349 FR0202349W WO03005032A3 WO 2003005032 A3 WO2003005032 A3 WO 2003005032A3 FR 0202349 W FR0202349 W FR 0202349W WO 03005032 A3 WO03005032 A3 WO 03005032A3
Authority
WO
WIPO (PCT)
Prior art keywords
cys
lys
ala
bind
protein
Prior art date
Application number
PCT/FR2002/002349
Other languages
English (en)
Other versions
WO2003005032A2 (fr
Inventor
Claudio Vita
Catherine Royer
Vivian Pogenberg
Original Assignee
Commissariat Energie Atomique
Inst Nat Sante Rech Med
Claudio Vita
Catherine Royer
Vivian Pogenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique, Inst Nat Sante Rech Med, Claudio Vita, Catherine Royer, Vivian Pogenberg filed Critical Commissariat Energie Atomique
Priority to CA002452663A priority Critical patent/CA2452663A1/fr
Publication of WO2003005032A2 publication Critical patent/WO2003005032A2/fr
Publication of WO2003005032A3 publication Critical patent/WO2003005032A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à un procédé de criblage de molécules aptes à se lier à la protéine gp120 du virus de l'immunodéficience.Le procédé de la présente invention utilise la technique d'anisotropie de fluorescence et le peptide de formule (I) suivante : TPA- Xaaa- Xaab- Ala ou Gln ou His - Arg ou Phe - Cys - Xaac- Xaad- Arg - Cys - Lys - Xaae- Xaaf- Xaag- Xaah- Leu ou Lys - Xaai - Lys - Cys - Ala ou Gln - Gly ou (D)Asp ou Ser - Ser ou His ou Asn - Xaaj- Cys - Thr ou Ala - Cys - Xaak-NH2, (I) dans laquelle TPA représente l'acide thiopropionique, Xaaa, Xaab, Xaac, Xaad, Xaae, Xaaf, Xaag, Xaah, et Xaai, sont des acides aminés, naturels ou non naturels, identiques ou différents, Xaaj représente la b-naphtylalanine ou la phénylalanine ou la bi-phénylalanine, et Xaak représente Gly ou Val ou Ile.
PCT/FR2002/002349 2001-07-06 2002-07-04 Procede de criblage de molecules aptes a se lier a la proteine gp120 du virus de l'immunodeficience WO2003005032A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002452663A CA2452663A1 (fr) 2001-07-06 2002-07-04 Procede de criblage de molecules aptes a se lier a la proteine gp120 du virus de l'immunodeficience

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0109015A FR2827046B1 (fr) 2001-07-06 2001-07-06 Procede de criblage de molecules aptes a se lier a la proteine gp120 du virus de l'immunodeficience
FR01/09015 2001-07-06

Publications (2)

Publication Number Publication Date
WO2003005032A2 WO2003005032A2 (fr) 2003-01-16
WO2003005032A3 true WO2003005032A3 (fr) 2003-12-04

Family

ID=8865218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/002349 WO2003005032A2 (fr) 2001-07-06 2002-07-04 Procede de criblage de molecules aptes a se lier a la proteine gp120 du virus de l'immunodeficience

Country Status (3)

Country Link
CA (1) CA2452663A1 (fr)
FR (1) FR2827046B1 (fr)
WO (1) WO2003005032A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023474A1 (fr) * 1998-10-21 2000-04-27 The University Of Queensland Ingenierie des proteines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023474A1 (fr) * 1998-10-21 2000-04-27 The University Of Queensland Ingenierie des proteines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DRAKOPOULOU EUGENIA ET AL: "Engineering a CD4 mimetic inhibiting the binding of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein gp120 to human lymphocyte CD4 by the transfer of a CD4 functional site to a small natural scaffold.", LETTERS IN PEPTIDE SCIENCE, vol. 5, no. 2-3, May 1998 (1998-05-01), pages 241 - 245, XP008003798, ISSN: 0929-5666 *
DRAKOPOULOU, EUGENIA ET AL: "Engineering a CDR2 sequence of hCD4 into the.alpha./.beta. scaffold of charybdotoxin", PEPTIDES 1996, PROCEEDINGS OF THE EUROPEAN PEPTIDE SYMPOSIUM, 24TH, EDINBURGH, SEPT. 8-13, 1996 (1998), MEETING DATE 1996, 345-346. EDITOR(S): RAMAGE, ROBERT;EPTON, ROGER. PUBLISHER: MAYFLOWER SCIENTIFIC, KINGSWINFORD, UK., 1998, XP001073762 *
MARTIN L ET AL: "Engineering Novel Bioactive Mini-Proteins on Natural Scaffolds", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 56, no. 48, 24 November 2000 (2000-11-24), pages 9451 - 9460, XP004220792, ISSN: 0040-4020 *
VITA CLAUDIO ET AL: "RATIONAL ENGINEERING OF A MINIPROTEIN THAT REPRODUCES THE CORE OF THE CD4 SITE INTERACTING WITH HIV-1 ENVELOPE GLYCOPROTEIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 23, 9 November 1999 (1999-11-09), pages 13091 - 13096, XP002181795, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2003005032A2 (fr) 2003-01-16
FR2827046A1 (fr) 2003-01-10
FR2827046B1 (fr) 2004-01-23
CA2452663A1 (fr) 2003-01-16

Similar Documents

Publication Publication Date Title
EP2343318A3 (fr) Anticorps se liant à un fragment C-terminal de l'apolipoprotein E
HUP0004639A2 (hu) Chlamydia fehérje, génszekvencia és ezek alkalmazása
WO2002044215A3 (fr) Produit
WO2004092199A3 (fr) Procede d'identification de modulateurs de la signalisation de recepteur couple a une proteine g
CA2450476A1 (fr) Complexe soluble contenant une glycoproteine de surface retrovirale
WO2002062851A8 (fr) Proteines tau
WO2002074981A3 (fr) Dosages, procedes et dispositifs
CA2363947A1 (fr) Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
WO2003008454A3 (fr) Proteine de fusion, glycoproteine vi
ATE460430T1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
WO2005056585A3 (fr) Protéines s du coronavirus du sars et leurs utilisations
WO2006131749A3 (fr) Echafaudage
HK1093308A1 (en) Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock
WO2002059146A3 (fr) Peptides presentant une affinite pour la proteine virale gp120, et utilisation de ces peptides
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
WO2003060098A3 (fr) Methodes d'identification de composes qui inhibent la liaison de la proteine 7 de nucleocapside 7 a l'arn du hiv-1
WO2003005032A3 (fr) Procede de criblage de molecules aptes a se lier a la proteine gp120 du virus de l'immunodeficience
WO2000070351A3 (fr) Interactions proteine-proteine et techniques permettant d'identifier des proteines interagissant et la sequence d'acides amines au niveau du site d'interaction
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2004050870A3 (fr) Interrupteurs genetiques pour la detection de proteines de fusion
WO2005116658A3 (fr) Methode de determination d'un processus de degradation tissulaire par detection de neoepitopes comp
WO2001002429A3 (fr) Angiopoietine 6 et ses utilisations
TATsUMI et al. Deterioration of connectin/titin and nebulin filaments by an excess of protease inhibitors
CA2385766A1 (fr) Methodes de production de proteines dans des cellules hotes
WO2002073209A3 (fr) Procede d'identification d'epitopes immunoreactifs sur des proteines et utilisation desdits epitopes a des fins prophylactiques et therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003510957

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2452663

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP